{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
telotristat ethyl
to a specific field?
Status:
Investigational
Source:
Br J Nutr. Nov 2008;100(5):937-41.: Not Applicable Human clinical trial Completed Hypercholesterolemia/metabolism
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Stigmasterol (also known as Wulzen anti-stiffness factor) is a plant sterol, or phytosterol. Recent investigation discovered that this compound could be new promising anti- Methicillin-resistant Staphylococcus aureus agent.
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Epinine or deoxyepinephrine is an active form of Ibopamine, which is used as a cardiovascular agent in congestive heart failure. Epinine is a stimulant of alpha-adrenoceptor activities: alpha-1 and alpha-2. Experiments on pig’s eyes have shown that epinine can be a promising candidate substance for intraoperative (e.g., cataract surgery) intracameral use in humans.
Status:
Investigational
Source:
NCT00884520: Early Phase 1 Interventional Completed Lung Cancer
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01019928: Phase 2 Interventional Completed Sensitivity in Esophagus
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00915356: Phase 2 Interventional Completed Atrial Fibrillation
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
AZD1305, an antiarrhythmic agent, blocks the hERG potassium channel, the L-type calcium, and the Sodium channel protein Nav1.5. AZD1305 participated in clinical trials for the management of atrial fibrillation and Left ventricular dysfunction. The benefit-risk profile was judged as unfavorable and the AZD1305 development programme was discontinued.
Status:
Investigational
Source:
NCT00713544: Phase 2 Interventional Completed Rheumatoid Arthritis
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
AZD5672 was developed by AstraZeneca for the treatment of rheumatoid arthritis. It was found that the drug inhibits P-glycoprotein and is a CCR5 antagonist. Exists hypothesis that inhibition of CCR5 can bring benefits in the treatment of rheumatoid arthritis. In July 2009, Phase-II for Rheumatoid arthritis was discontinued.
Status:
Investigational
Source:
NCT04251182: Phase 2 Interventional Completed Alzheimer Disease
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
JAN:L-TYROSINE ETHYLESTER MONOHYDROCHLORIDE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Tyrosine ethyl ester hydrochloride is used as a medical and organic intermediate and as an important amino protective agent. It is also used to introduce t-Boc protect gene. Tyrosine ethyl ester hydrochloride is used as a supplement (tyrosine).
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Thimerfonate is a alkyl mercuric derivative with germicidal activity.
Status:
Investigational
Source:
NCT00002121: Phase 1 Interventional Completed Diarrhea
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Diethylhomospermine is the polyamine analogue. It suppressed the activity of the major biosynthetic enzymes, ornithine decarboxylase and S-adenosylmethionine decarboxylase in human bladder cancer cell lines. Diethylhomospermine given as the subcutaneous injection is overall well tolerated at lower doses, but significant toxicities were observed at the 37.5mg/m2/day dose level. Maximal tolerated dose was established at 25 mg/m2/day but further investigation with this study drug is not recommended secondary to the potential for neurotoxicities and hepatic damage as a result of cumulative doses. Diethylhomospermine had been in phase II clinical trials for the treatment of AIDS-related chronic diarrhea. However, this research has been discontinued.
